Kilitch Drugs (India) Ltd.



May 3, 2019

To Department of Corporate Services **BSE Limited** P. J. Towers, Dalal Street Fort, Mumbai - 400 001 Scrip Code: **BSE - 524500** То

Corporate Listing Department **National Stock Exchange of India Ltd** Exchange Plaza, Plot No.C-1, G Block, BKC, Bandra (E), Mumbai 400 051 Scrip Code: **NSE - KILITCH**

Sub: Outcome of Board Meeting held on May 3, 2019

Dear Sir/Madam,

In continuation to our letter dated April 25th 2019, we wish to inform you that pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 3rd May, 2019, have considered & approved the Allotment of 62239 Equity shares pursuant to exercise of option granted to employees of the Company under ESOS Scheme.

The meeting commenced at 11:00 A.M. and concluded at 12.00 P.M.

The above is for information and dissemination to the public at large.

Thanking You,

Yours Faithfully, For **Kilitch Drugs (India) Limited**

Bhavin Mehta Wholetime Director *DIN: 00147895*





Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. •Tel.: +91-22-6121 4100 • Fax : +91-22-6703 1658 Registered Office & Manufacturing unit : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra. • CIN: L24239MH1992PLC066718 • Tel.: +91-22-2767 0322 / 2768 0913 • Fax : +91-22-2768 0912 • E-mail : info@kilitch.com • Website : www.kilitch.com